CARA Stock Earnings: Cara Therapeutics Misses EPS, Misses Revenue for Q4 2023

    Date:

    Cara Therapeutics (NASDAQ:CARA) just reported results for the fourth quarter of 2023.

    • Cara Therapeutics reported earnings per share of -59 cents. This was below the analyst estimate for EPS of -41 cents.
    • The company reported revenue of $3.00 million.
    • This was 68.11% worse than the analyst estimate for revenue of $9.42 million.

    InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com.

    Go Source

    Chart

    SignUp For Breaking Alerts

    New Graphic

    We respect your email privacy

    Share post:

    Popular

    More like this
    Related

    China Economic Work Conference Dates Announced

    Key News Asian equities had a strong day as Indonesia...

    Market watchers getting squeezed

    There was a good billing to begin the month...

    Chart Advisor: Fresh Eyes on Docusign

    From SIA Charts 1/ Docusign Inc. (DOCU) 2/ Candlestick Chart 3/ Point and...

    Estimize Part Two: The Wisdom of Give-to-Get

    Part One of this series examines the concept of...